Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Trend towards high-dose, once-daily mesalazine for ulcerative colitis

by Lin-Nam Wang

Clinical trials and hospitals are beginning to use higher doses of mesalazine for ulcerative colitis, according to Anja St. Clair Jones, lead pharmacist, surgery and digestive disease at Brighton and Sussex University Hospitals NHS Trust.

In a prescribing and medicines management article, she writes that although the European Crohn’s and Colitis Organisation recommends a minimum daily dose of 1g to maintain remission, evidence is emerging that daily doses of 2g and above may be more effective.

Moreover, non-adherence in patients in remission can be a big problem, with considerable clinical impact. One study, for example, found that adherence to therapy reduces the risk of colorectal cancer by 75 per cent. Mrs St. Clair Jones argues that, bearing in mind the importance of adherence, cheaper preparations that mean a high tablet burden or large tablets may not be the best option.

Citation: The Pharmaceutical Journal URI: 11021798

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Colon

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.